Novo Nordisk

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments.

CEO

Lars Fruergaard Jørgensen

CEOLars Fruergaard Jørgensen

Employees

54,393

Employees54,393

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1931

Founded1931

Employees

54,393

Employees54,393

NVO Key Statistics

Market cap

386.44B

Market cap386.44B

Price-Earnings ratio

43.48

Price-Earnings ratio43.48

Dividend yield

0.80%

Dividend yield0.80%

Average volume

4.46M

Average volume4.46M

High today

$90.93

High today$90.93

Low today

$86.96

Low today$86.96

Open price

$89.60

Open price$89.60

Volume

4.73M

Volume4.73M

52 Week high

$100.88

52 Week high$100.88

52 Week low

$50.45

52 Week low$50.45

NVO News

Benzinga 15h

Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner

Novo Nordisk A/S NVO successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs, Wegovy and Oze...

Reuters 17h

Novo Nordisk owner sees chance to go public will open within 18 ... - Reuters

COPENHAGEN, Oct 3 (Reuters) - The CEO of Novo Holdings, the controlling shareholder in drugmaker Novo Nordisk (NOVOb.CO), said on Tuesday he sees the window for...

Fortune 1d

Ozempic and Wegovy ‘significantly’ improve blood sugar and weight for the long-term, new study suggests - Fortune

Semaglutides—weight loss and diabetes injectables like Wegovy, Ozempic, and Rybelsus—significantly improved blood sugar control and weight in adults with type 2...

Analyst ratings

61%

of 28 ratings

Buy

60.7%

Hold

25%

Sell

14.3%

NVO Earnings

$0.00

$0.21

$0.43

$0.64

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Q1 FY23

Q2 FY23

Q3 FY23

Estimated

$0.48 per share

Estimated$0.48 per share

Actual

Available Nov 2

ActualAvailable Nov 2

More NVO News

Yahoo Finance 1d

Novo Nordisk Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

Novo Nordisk (NVO) closed the most recent trading day at $91.80, moving +0.95% from the previous trading session. This move outpaced the S&P 500's daily gain of...

Reuters 1d

US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic

FILE PHOTO: Flags with the Novo Nordisk logo flutter outside their Danish company's offices in Copenhagen By Blake Brittain WASHINGTON (Reuters) - A U.S. Pate...

Reuters 1d

Drugmakers sign on to negotiate Medicare prices under protest - Reuters

U.S. President Joe Biden delivers remarks on Social Security and Medicare at the University of Tampa in Tampa, Florida, U.S. February 9, 2023. REUTERS/Jonathan...

Yahoo Finance 2d

US FDA approves Novo Nordisk's therapy for rare genetic condition - Yahoo Finance

Oct 2 (Reuters) - Novo Nordisk said on Monday the U.S. Food and Drug Administration (FDA) had approved its therapy to treat a rare genetic condition that affect...

Benzinga 2d

FDA approves Rivfloza™ for children ≥9 years old and adults living ... - Benzinga

PLAINSBORO, N.J., Oct. 2, 2023 /PRNewswire/ -- Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved RivflozaTM (nedosiran)...

Yahoo Finance 2d

Novo Nordisk A/S - share repurchase programme - Yahoo Finance

Novo Nordisk A/S Bagsværd, Denmark, 02 October 2023 – On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Re...

CNBC 4d

Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data

Shares of Structure Therapeutics rose more than 30% on Friday after the biotech startup's experimental obesity pill succeeded in a small early-stage trial. The...